For chronic kidney disease (CKD) on dialysis. ANDA 209226, held by Strides Pharma. Cinacalcet Hydrochloride.
As of Nov 16, 2026, ANDA 209226 (Cinacalcet Hydrochloride), held by Strides Pharma, was first approved by FDA on Apr 30, 2018, with 2 approved supplements and 0 published complete response letters.
Cinacalcet is a positive modulator of the calcium sensing receptor indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2018 | Original application | Approved | None posted |
| Cinacalcet HydrochlorideEQ 30MG BASE · tablet;oral | Cinacalcet Hydrochloride | Rx |
| Cinacalcet HydrochlorideEQ 60MG BASE · tablet;oral | Cinacalcet Hydrochloride | Rx |
| Cinacalcet HydrochlorideEQ 90MG BASE · tablet;oral | Cinacalcet Hydrochloride | Rx |
| May 18, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 18, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 30, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters